Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cantor Fitzgerald Reiterates Overweight on Mesoblast

Author: Benzinga Newsdesk | June 20, 2024 01:41pm
Cantor Fitzgerald analyst Louise Chen reiterates Mesoblast (NASDAQ:MESO) with a Overweight.

Posted In: MESO